ANTISOMA REPORTS PRECLINICAL AS1404 DATA

Antisoma has reported that preclinical trials of its cancer drug AS1404 have shown a clear additional benefit when combined with the appropriate taxane compared with treatment with the taxane alone.

AS1404, a vascular disrupting agent, is undergoing three randomized controlled Phase II trials in lung, prostate and ovarian cancers, each asking whether addition of AS1404 to a taxane-based regimen provides extra benefit to patients.

Some cures were seen among animals treated with AS1404 taxane combinations but not in any of those receiving a taxane alone.